

Press release

Ad hoc announcement pursuant to Art. 53 LR

Date 7 August 2025
Contact Investor Relations: investors@galenica.com / +41 58 852 85 31
Media Relations: media@galenica.com / +41 58 852 85 17
Subject Galenica Group half-year results 2025

Galenica demonstrates pleasing growth and improves EBIT guidance

- **Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.**
- **Adjusted EBIT¹ increased by 10.9% to CHF 109.9 million – supported by positive one-off effects of CHF 5.4 million.**
- **Galenica is therefore raising its EBIT guidance and now expects growth between 7% and 9% (previously growth between 4% and 6%).**
- **Guidance for 2025 sales growth remains unchanged at 3% to 5%, the dividend is expected to remain at least at the previous year's level.**

Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the "Products & Care" segment (+4.6%) and the "Logistics & IT" segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%²) and the consumer healthcare market (+0.6%³).

Strong sales growth in prescription drugs

Following an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based⁴ weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year.

Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT¹ increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT¹ would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the "Logistics & IT" segment.

Improved EBIT guidance for the second half of the year

Galenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT¹ increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected.

Galenica Ltd.

Untermattweg 8 | P.O. Box | CH-3001 Bern
+41 58 852 81 11 | info@galenica.com | galenica.com

Galenica – Health and well-being are at the heart of what we do.

Date 7 August 2025
Page 2/3
Subject Galenica Group half-year results 2025

In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance.

Key figures of the Galenica Group in the first half of 2025

(in million CHF)	1st half of 2025	1st half of 2024	Change
Net sales			
Products & Care segment	867.3	829.3	+4.6%
- Retail (B2C)	731.1	695.4	+5.1%
Local Pharmacies	693.1	657.6	+5.4%
Pharmacies at Home	38.1	37.9	+0.3%
- Professionals (B2B)	140.9	138.4	+1.8%
Products & Brands	97.8	97.0	+0.9%
Services for Professionals	43.1	41.4	+4.0%
Logistics & IT segment	1,649.7	1,563.3	+5.5%
Wholesale	1,579.6	1,496.5	+5.6%
Logistics & IT Services	83.0	77.7	+6.9%
Corporate and eliminations	-521.7	-492.6	
Galenica Group	1,995.4	1,900.0	+5.0%
EBIT adjusted¹			
Products & Care segment	79.5	75.9	+4.6%
Logistics & IT segment	32.0	25.4	+25.8%
Corporate and eliminations	-1.6	-2.2	
Galenica Group	109.9	99.1	+10.9%
Net profit from ongoing business activities adjusted¹	90.7	77.7	+16.8%

Detailed information in the half year report 2025:

- [Management report of the Galenica Group](#)
- [Management report for the Products & Care segment](#)
- [Management report for the Logistics & IT segment](#)
- [Key figures](#)

Date 7 August 2025
Page 3/3
Subject Galenica Group half-year results 2025

Conference call at 2 p.m.

Galenica will host a Zoom Conference Call on the results for the first half of 2025 today, Thursday, 7 August 2025, at 2 p.m. (CEST). You can follow the Zoom conference via this link: [Zoom conference](#) (meeting: 880 3349 4358, code: 2466)

The conference will be held in German with simultaneous English interpreting. The presentation will be available on the [website](#) from around 12 noon (CEST) on 7 August 2025. A recording of the conference call will then be made available on the [website](#).

Dates for the diary

23 October 2025	Galenica Group sales update
28 October 2025	Galenica Investor Day 2025
22 January 2026	Galenica Group sales update

For further information, please contact:**Media Relations:**

Tel. +41 58 852 85 17
Email: media@galenica.com

Investor Relations:

Tel. +41 58 852 85 31
Email: investors@galenica.com

Welcome to the Galenica network!

Around 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally.

Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Find out more about Galenica at www.galenica.com.

1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the [half year report 2025](#))

2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025.

3) IQVIA, Consumer Health Market Switzerland, YTD June 2025.

4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.